| Literature DB >> 32416844 |
Yanfen Ma1, Shuo Zhou1, Xin Lin1, Weidong Zeng1, Yuling Mi1, Caiqiao Zhang2.
Abstract
N-carbamylglutamate (NCG), an analogue of N-acetyl-L-glutamate (NAG), can increase arginine synthesis in mammals and improve the reproductive performance. However, the effect of NCG on poultry laying performance is still unclear. This study investigated the effect of dietary NCG on development of chicken ovarian follicles. The dosage and timing for NCG administration were evaluated for its effect on follicular development. Results showed that supplementation with 1% NCG in the diet for 14 D led to accelerated development of growing follicles (over 60 μm in oocyte diameter) and significantly increased feed intake and feed efficiency. Plasma amino acids (AA) analysis showed that feeding with 1% NCG significantly increased of plasma AA levels. RNA-seq analysis revealed that NCG supplementation upregulated expression of genes related to angiogenesis and cell proliferation, but downregulated expression of apoptosis-related genes. Meanwhile, RT-qPCR and Western blot analysis validated the RNA-seq results. Moreover, NCG enhanced plasma NO level; upregulated expression of PKG-I, Raf1, and p-p38; and increased angiogenesis of the ovaries. In conclusion, dietary NCG (1% for 14 D) can promote development of ovarian follicles by increasing angiogenesis in ovaries of the chicken.Entities:
Keywords: N-carbamylglutamate; NO; angiogenesis; chicken; follicles
Mesh:
Substances:
Year: 2019 PMID: 32416844 PMCID: PMC7587619 DOI: 10.3382/ps/pez545
Source DB: PubMed Journal: Poult Sci ISSN: 0032-5791 Impact factor: 4.014
Composition and nutrient level of the basal diets.
| Ingredients | Content (%) |
|---|---|
| Corn | 65.5 |
| Bran | 2.5 |
| Soybean meal | 29 |
| Premix | 3 |
Supplied per kilogram of premix: dl-a-tocopherol acetate ≥280 mg; sodium menadiene bisulfite, 30 ∼ 96 mg; thiamine nitrate ≥38 mg; vitamin B2 ≥ 60 mg; pyridoxine hydrochloride ≥60 mg; vitamin B12 ≥ 0.2 mg; nicotinamide ≥420 mg; D-calcium pantothenate ≥420 mg; folic acid ≥12.0 mg; D-biotin ≥3.0 mg; choline chiorlde ≥5.6 g; vitamin A acetate, 160,000 ∼ 200,000 IU; vitamin D3, 4.4 ∼ 100 mg; Cu, 140 ∼ 420 mg; Fe, 1.6 × 103 ∼ 1.3 × 104; Mn, 1.2 × 103 ∼ 3.0 × 103; Zn, 1.2 × 103 ∼ 2.4 × 103; Se, 2.0 ∼ 6.0 mg; I, 6.0 ∼ 18 mg; methionine, 2.6 ∼ 5.2%; P, 1.8 ∼ 5.0%; Ca, 5.0 ∼ 20%; NaCl, 4.0 ∼ 9.0%; H2 O2 ≤ 10.
Sequences of the primers for PCR.
| Gene name | Accession no. | Primer sequence (5′-3′) | Product size (bp) |
|---|---|---|---|
| NM_205,381.1 | F: CCTCAAGAAAAGCCGGTTGC | 86 | |
| R: CTGCGGTCAGAGGAATCGTT | |||
| NM_0,011,99857.1 | F: TCCGTATCTTCCGCACGTTG | 183 | |
| R: GCTTGTTGGGATCGTAGTGC | |||
| Caspase-3 | NM_204,725.1 | F: CAGCTGAAGGCTCCTGGTTT | 98 |
| R: GCCACTCTGCGATTTACACG | |||
| NM_0,011,10355.1 | F: GTCGTACATATTCAGGCCATC | 197 | |
| R: GATTCTTTGGTCTGCAGTCAC | |||
| JQ434761.1 | F: GAACCCCCAAGACCTACGTGC | 180 | |
| R: CCTGCCCCATGGTCATTCCTC | |||
| β-actin | NM_205,518 | F: ACACCCACACCCCTGTGATGAA | 136 |
| R: TGCTGCTGACACCTTCACCATTC |
Figure 1Effect of different doses of N-carbamylglutamate (NCG) on follicular development. (A) hematoxylin and eosin (HE) staining was used to evaluate the different doses of NCG on follicular development. Scale bar: 100 μm. (B) The ratio of ovary/BW after NCG administration. (C) The number of follicles in the cortex after NCG administration. (D) The number of follicles with different oocyte diameter. Different lowercase letters indicated significant difference (P < 0.05).
Figure 2Effect of N-carbamylglutamate (NCG) on changes in follicular diameter at different feeding time. (A) Ovarian morphology by hematoxylin and eosin (HE) staining after NCG administration at 7 D, 14 D, and 21 D. (B) The number of follicles with different diameter of oocytes. Different lowercase letters indicated significant difference (P < 0.05).
Figure 3Effect of N-carbamylglutamate (NCG) on feed intake, BW gain, and feed conversion ratio (P < 0.05).
Effect of NCG feeding on plasma AA levels in chickens.
| Control | 1% NCG | |||
|---|---|---|---|---|
| AA (g/100 g Plasma) | Mean | SEM | Mean | SEM |
| Asp | 0.075 | 0.0011 | 0.095 | 0.0042 |
| Thr | 0.038 | 0.0015 | 0.048 | 0.0012 |
| Ser | 0.041 | 0.0010 | 0.052 | 0.0018 |
| Glu | 0.138 | 0.0027 | 0.171 | 0.0036 |
| Gly | 0.023 | 0.0005 | 0.031 | 0.0014 |
| Ala | 0.041 | 0.0009 | 0.050 | 0.0014 |
| Cys | 0.026 | 0.0010 | 0.037 | 0.0007 |
| Val | 0.039 | 0.0007 | 0.046 | 0.0014 |
| Met | 0.017 | 0.0005 | 0.023 | 0.0011 |
| Ile | 0.030 | 0.0014 | 0.040 | 0.0005 |
| Leu | 0.067 | 0.0023 | 0.081 | 0.0012 |
| Tyr | 0.029 | 0.0012 | 0.039 | 0.0009 |
| Phe | 0.029 | 0.0007 | 0.040 | 0.0007 |
| Lys | 0.045 | 0.0015 | 0.056 | 0.0011 |
| His | 0.018 | 0.0005 | 0.022 | 0.0007 |
| Arg | 0.043 | 0.0009 | 0.057 | 0.0020 |
| Pro | 0.022 | 0.0005 | 0.026 | 0.0008 |
Means within a row with different letters differ (P < 0.05).
Figure 4KEGG analysis of differentially expressed genes between control group and N-carbamylglutamate (NCG) group. The size of dot indicated the number of differential genes. The Y-axis and X-axis indicated functional pathways and rich factor.
Differentially expressed genes involved in angiogenesis, proliferation, and apoptosis of chicken ovaries.
| Gene ID | log2 FC | Gene symbol | Description |
|---|---|---|---|
| Upregulated genes | |||
| ENSGALG00000008612 | 1.0855 | MAPK11 | Serine/threonine/dual specificity protein kinase |
| ENSGALG00000007130 | 0.56057 | cRac1A | Small GTPase superfamily, ARF/SAR type |
| ENSGALG00000010290 | 0.690431388 | VEGFA | Vascular endothelial growth factor A |
| ENSGALG00000000619 | 1.229192093 | ANGPTL4 | Angiopoietin like 4 |
| ENSGALG00000003943 | 0.61655 | PRKCA | Tyrosine-protein kinase, catalytic domain |
| ENSGALG00000002583 | 0.94258 | PIK3CD | Phosphoinositide 3-kinase, accessory (PIK) domain |
| ENSGALG00000000169 | 0.26220019 | PCNA | Proliferating cell nuclear antigen |
| ENSGALG00000010978 | 0.733954755 | ANGPTL3 | Angiopoietin like 3 |
| ENSGALG00000027798 | 1.07208274 | CDK2 | Cyclin dependent kinase 2 |
| ENSGALG00000010847 | 0.60128 | VEGFC | Vascular endothelial growth factor C |
| ENSGALG00000010346 | 0.394403223 | TGFB3 | TGFB3 |
| ENSGALG00000000883 | 0.29463 | MAPKAPK2 | Tyrosine-protein kinase, catalytic domain |
| ENSGALG00000006014 | 0.73038 | PRKCB | Protein kinase C beta |
| ENSGALG00000027946 | 0.25803602 | NOS3 | Nitric oxide synthase 3 |
| ENSGALG00000001501 | 0.35888 | MAPK1 | Mitogen-activated protein (MAP) kinase, ERK1/2 |
| ENSGALG00000008462 | 0.388697039 | CDK3 | Cyclin dependent kinase 3 |
| ENSGALG00000000826 | 1.5124 | MAPK13 | Mitogen-activated protein (MAP) kinase, p38 |
| ENSGALG00000011620 | 0.42019 | AKT1 | Pleckstrin homology domain |
| ENSGALG00000005065 | 0.42708 | PLA2G4A | Lysophospholipase, catalytic domain |
| ENSGALG00000004998 | 0.27178 | RAF1 | Raf-like Ras-binding |
| ENSGALG00000004290 | 0.469614321 | ANGPTL1 | Angiopoietin like 1 |
| ENSGALG00000007555 | 0.3221956 | CCND1 | Cyclin D1 |
| ENSGALG00000003085 | 0.81682609 | CDK1 | Cyclin dependent kinase 1 |
| ENSGALG00000009062 | 0.304761106 | CDK14 | Cyclin dependent kinase 14 |
| ENSGALG00000006038 | 0.21550712 | TGFBR3 | Transforming growth factor beta receptor 3 |
| Downregulated genes | |||
| ENSGALG00000008933 | −0.32531148 | CASP7 | Peptidase C14, caspase domain |
| ENSGALG00000008934 | −0.62104 | PIK3CA | Phosphoinositide 3-kinase, accessory (PIK) domain |
| ENSGALG00000002859 | −0.39812 | RAC3 | Mitochondrial Rho-like |
| ENSGALG00000014790 | −0.287482558 | CDK7 | Cyclin dependent kinase 7 |
| ENSGALG00000016171 | −0.77253 | FAK | Ubiquitin-related domain |
| ENSGALG00000011442 | −0.117947066 | TGFBR2 | Transforming growth factor beta receptor 2 |
| ENSGALG00000010638 | 0.525196291 | CASP3 | Peptidase C14, caspase domain |
| ENSGALG00000001267 | −0.51013 | MAP2K2 | Mitogen-activated protein kinase 2 |
| ENSGALG00000014786 | −0.69634 | PIK3R1 | Rho GTPase activation protein |
| ENSGALG00000006885 | −1.003 | H-RAS | Small GTPase superfamily, Ras type |
| ENSGALG00000012885 | −0.5992686 | BCL2 | BCL2, apoptosis regulator |
Figure 5Effect of N-carbamylglutamate (NCG) on angiogenesis in the ovary. (A) Immunofluorescent staining of CD31. White arrowheads: blood vessels. Scale bar: 50 μm. (B) Immunohistochemistry of vascular endothelial growth factor (VEGF) in the ovaries. Scale bar: 50 μm. (C) Change in VEGF and NOS3 mRNA expression. (D) Relative expression of VEGF protein. Different lowercase letters indicated significant difference (P < 0.05).
Figure 6Effect of N-carbamylglutamate (NCG) on proliferation of ovarian somatic cells. (A) Immunohistochemistry of proliferating cell nuclear antigen (PCNA) in the ovaries. Scale bar: 50 μm. (B) Expression of proliferation-associated gene CCND1 and CDK2 changes. (C) Relative expression of PCNA, CCND1, and CDK2. Different lowercase letters indicated significant difference (P < 0.05).
Figure 7Effect of N-carbamylglutamate (NCG) on apoptosis of ovarian somatic cells. (A) Immunohistochemistry of Bax in the ovaries. Scale bar: 50 μm. (B) Expression of apoptosis-associated gene caspase-3 changes. (C) Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) index of ovary tissues. Scale bar: 50 μm. Different lowercase letters indicated significant difference (P < 0.05).
Figure 8Effect of N-carbamylglutamate (NCG) on changes in plasma NO levels and expression of PKG-I, Raf1, p-p38. (A) Plasma NO levels. (B) Expression of PKG-I, Raf1, and p-p38 proteins. Different lowercase letters indicated significant difference (P < 0.05).